BioMarin's Voxzogo sNDA Accepted by FDA, Full Approval Path Cleared

BioMarin Pharmaceutical Inc. announced on July 13, 2026, that the United States Food and Drug Administration accepted its supplemental New Drug Application (sNDA) for vosoritide (Voxzogo). The sNDA seeks full approval to treat children with achondroplasia aged five and older and includes data supporting long-term efficacy and safety. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2027, initiating a standard 6-month review for a drug already on the market under accelerated approval. BioMarin's stock (BMRN) traded at $107.80, up 2.4% in premarket activity following the news.

Context — [why this matters now]

Voxzogo holds the distinction of being the first approved therapy for achondroplasia, receiving FDA accelerated approval in November 2021 and European Commission conditional approval in August 2021. The transition from accelerated to full FDA approval is a critical regulatory milestone observed in oncology and rare disease spaces, such as Merck's Keytruda in certain cancers and Vertex's Kalydeco in cystic fibrosis. The current review occurs in a supportive regulatory environment for rare disease therapies, evidenced by the FDA's 2025 approval of 15 novel drugs for rare conditions. The catalyst for this filing was the accumulation of over five years of continuous treatment data from the Phase 3 extension study, which provided the long-term growth and safety profile required for a traditional approval.

BioMarin's application leverages data showing sustained height velocity benefit and a well-established safety profile through 260 weeks of treatment. The company strategically timed this filing to align with its commercial expansion goals for the drug. The FDA uses the standard review timeline for this sNDA, distinct from a priority review, reflecting the non-urgent supplemental nature of the application for an already-marketed product. The agency's acceptance confirms the submitted data package is complete, avoiding a refuse-to-file letter, a positive procedural step.

Data — [what the numbers show]

Voxzogo generated $742 million in global net product revenue in 2025, representing a 28% year-over-year increase. BioMarin guides for 2026 Voxzogo sales of approximately $1.5 billion. The drug's annual list price in the United States is approximately $350,000 per patient. As of March 2026, over 3,800 patients globally were receiving commercial therapy, an increase of over 900 patients from the prior quarter.

Market projections for the achondroplasia therapy market exceed $5 billion annually by 2030. BioMarin's market capitalization stands at $20.1 billion. The company's shares have gained 18% year-to-date, outperforming the iShares Biotechnology ETF (IBB), which is up 5% over the same period. A 260-week data set from the extension study underpins the sNDA, showing a mean increase in annualized height velocity of +1.57 cm/year for treated children versus matched natural history cohorts.

Voxzogo's gross margin improved to 89% in 2025. The therapy is approved in over 40 countries. The Phase 3 study enrolled 121 children with achondroplasia. The PDUFA date of January 13, 2027, establishes a clear 6-month regulatory timeline for investors.

Analysis — [what it means for markets / sectors / tickers]

This sNDA acceptance is a procedural de-risking event for BioMarin, removing the overhang of a potential refuse-to-file decision. It solidifies Voxzogo's long-term commercial runway by potentially converting its U.S. label to a more durable full approval. The primary beneficiary is BioMarin (BMRN), where Voxzogo represents its fastest-growing revenue stream and a key driver of margin expansion. Secondary beneficiaries include contract manufacturers in BioMarin's supply chain and diagnostic labs involved in genetic testing for skeletal dysplasias.

A key limitation is that full approval does not inherently expand the labeled patient population; it reinforces the existing indication. The risk remains that payers could still impose restrictive prior authorization hurdles despite the label change. Competitive risk is emerging from Ascendis Pharma's TransCon CNP (skotrifin), which is in Phase 3 trials with top-line data expected in Q4 2026.

Positioning data from options markets shows increased call buying in BioMarin for January 2027 expiries, aligning with the PDUFA date. Institutional flow from healthcare-focused funds has been net positive for BMRN over the last quarter, with many viewing the sNDA as a low-risk, high-probability catalyst. Short interest in BMRN has declined to 3.5% of float, below the biotech sector average.

Outlook — [what to watch next]

The definitive catalyst is the FDA's decision by the PDUFA date of January 13, 2027. Investors will monitor the FDA's Oncologic Drugs Advisory Committee calendar for any potential panel meeting, though one is not currently scheduled. BioMarin's Q3 2026 earnings report, expected around November 5, 2026, will provide an update on Voxzogo's commercial traction and any early commentary from the FDA review.

Key levels for BioMarin's stock include technical resistance near $115, the 52-week high, and support at the 200-day moving average near $98. A successful approval could see the stock re-rate towards peer valuations based on peak sales multiples for Voxzogo. Should the FDA issue a Complete Response Letter, support near the $90 level, representing the pre-accelerated approval valuation in 2021, would be tested.

Further commercial milestones include potential label expansions into younger age groups and new geographic market launches in Asia-Pacific. Data presentations at the American Society of Human Genetics meeting in October 2026 may offer additional long-term efficacy insights.